Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been given a $8.00 price objective by analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential upside of 19.94% from the stock’s previous close.

A number of other research firms have also recently weighed in on ZYNE. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Maxim Group set a $32.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $35.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, May 13th. Jefferies Group LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Zynerba Pharmaceuticals in a research report on Thursday, May 25th. Finally, Roth Capital set a $30.00 target price on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, May 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $29.11.

Zynerba Pharmaceuticals (ZYNE) traded down 55.71% during trading on Monday, reaching $6.67. 8,999,057 shares of the company traded hands. The company’s market capitalization is $88.42 million. Zynerba Pharmaceuticals has a 52 week low of $5.93 and a 52 week high of $25.95. The firm has a 50-day moving average price of $17.81 and a 200-day moving average price of $19.61.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.04. Analysts forecast that Zynerba Pharmaceuticals will post ($2.46) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Analysts Give Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a $8.00 Price Target” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/07/oppenheimer-holdings-inc-analysts-give-zynerba-pharmaceuticals-inc-nasdaqzyne-a-8-00-price-target.html.

In other Zynerba Pharmaceuticals news, Chairman Armando Anido bought 5,000 shares of Zynerba Pharmaceuticals stock in a transaction dated Monday, May 15th. The stock was acquired at an average cost of $19.70 per share, for a total transaction of $98,500.00. Following the completion of the transaction, the chairman now directly owns 336,012 shares of the company’s stock, valued at $6,619,436.40. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James E. Fickenscher bought 5,200 shares of Zynerba Pharmaceuticals stock in a transaction dated Friday, May 12th. The stock was acquired at an average price of $19.82 per share, with a total value of $103,064.00. Following the completion of the transaction, the chief financial officer now directly owns 12,200 shares of the company’s stock, valued at $241,804. The disclosure for this purchase can be found here. 10.02% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth approximately $9,362,000. Vanguard Group Inc. raised its stake in shares of Zynerba Pharmaceuticals by 53.9% in the first quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock worth $8,559,000 after buying an additional 149,094 shares in the last quarter. Pennsylvania Trust Co purchased a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth about $2,366,000. Sphera Funds Management LTD. purchased a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth about $2,010,000. Finally, Granite Point Capital Management L.P. purchased a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth about $1,990,000. Institutional investors and hedge funds own 31.08% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.